共 50 条
- [1] First-in-human study of RLY-2608, a pan-mutant and isoform selective PI3Kα inhibitor, as a single agent in patients (pts) with advanced solid tumors and in combination with fulvestrant in pts with advanced breast cancer[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Saura, CristinaSanz, LuciaKim, JaniceJhaveri, Komal L.Guerrero, AngelOrtega, Pablo TolosaSchott, Anne F.Curigliano, GiuseppePerez, Cesar AugustoNanda, RitaHamilton, Erika P.Henry, Jason TimothyWisinski, Kari BraunSammons, Sarah L.Segar, Jennifer MargaretAix, Santiago PonceSirven, Milana BergaminoSpira, Alexander I.Schram, Alison M.Varkaris, Andreas
- [2] First-in-human global multi-center study of RLY-2608, a pan mutant and isoform selective PI3Kα inhibitor, as a single agent in advanced solid tumor patients and in combination with fulvestrant in patients with advanced breast cancer[J]. CANCER RESEARCH, 2023, 83 (05)Varkaris, AndreasHamilton, ErikaHenry, JasonSpira, Alexander I.Schram, Alison M.McGuinness, Julia E.Tan, GegeLi, XiaoyanHunter, TamiekaSamadani, RaminTimm, AlisonKaranovic, DjuroSubbiah, VivekPerez, Cesar A.
- [3] First-in-human global study of RLY-2608, a panmutant and isoform selective PI3Ka inhibitor, as a single agent in patients with advanced solid tumors and in combination with fulvestrant in patients with advanced breast cancer[J]. CANCER RESEARCH, 2024, 84 (09)Varkaris, AndreasJhaveri, KomalCabanas, Elena GarraldaSanz, LuciaKim, JanicePerez, Cesar A.Hamilton, ErikaSpira, Alexander I.Wisinski, KariGuerrero, AngelHenry, JasonAhnert, Jordi RodonTan, GegeLi, XiaoyanHummel, DianaHunter, TamiekaTimm, AlisonSamadani, RaminPuente-Poushnejad, ErikaKwak, EuniceMar, Brenton G.Schram, Alison M.
- [4] Discovery and characterization of RLY-2608: The first allosteric, mutant, and isoform-selective inhibitor of PI3Kα[J]. MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)Pazolli, ErmiraKipp, RandyBoezio, AlessandroGunaydin, HakanIskandar, AmandaZubrowski, MatthewWilliams, BretShortsleeves, KelleyLarivee, AlexandreMcLean, TomMichelsen, KlausZeng, HongtaoLaRochelle, JonathanManna, JoeDiPietro, LucianMader, MaryBennet, BinduWilbur, JeremyWang, QiPierce, LeviMartin, IainWatters, JamesFortin, PascalBergstrom, Donald
- [5] RLY-2608: The first allosteric mutant- and isoform-selective inhibitor of PI3Kα, is efficacious as a single agent and drives regressions in combination with standard of care therapies in PIK3CA mutant breast cancer models[J]. CANCER RESEARCH, 2022, 82 (04)Pazolli, ErmiraKipp, RandyBoezio, AlessandroGunaydin, HakanIskandar, AmandaZubrowski, MatthewWilliams, BretShortsleeves, KelleyLarivee, AlexandreMcLean, TomMichelsen, KlausZeng, HongtaoLaRochelle, JonathanManna, JoeDiPietro, LucianLescarbeau, AndreMader, MaryBennet, BinduWilbur, JeremyWang, QiPierce, LeviMartin, IainWatters, JamesFortin, PascalBergstrom, Donald
- [6] First-in-Human Trial of the PI3Kβ-Selective Inhibitor SAR260301 in Patients With Advanced Solid Tumors[J]. CANCER, 2018, 124 (02) : 315 - 324Bedard, Philippe L.Davies, Michael A.Kopetz, ScottJuric, DejanShapiro, Geoffrey I.Luke, Jason J.Spreafico, AnnaWu, BinCastell, ChristelleGomez, CorinneCartot-Cotton, SylvaineMazuir, FlorentDubar, MichelMicallef, SandrineDemers, BrigitteFlaherty, Keith T.
- [7] A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies[J]. CLINICAL CANCER RESEARCH, 2017, 23 (17) : 5015 - 5023Juric, Dejande Bono, Johann S.LoRusso, Patricia M.Nemunaitis, JohnHeath, Elisabeth I.Kwak, Eunice L.Macarulla Mercade, TeresaGeuna, Elenade Miguel-Luken, Maria JosePatel, ChiragKuida, KeisukeSankoh, SerapWestin, Eric H.Zohren, FabianShou, YapingTabernero, Josep
- [8] First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Burris, H.Rodon, J.Sharma, S.Herbst, R. S.Tabernero, J.Infante, J. R.Silva, A.Demanse, D.Hackl, W.Baselga, J.
- [9] A first-inhuman study of the highly selective PI3Ka inhibitor RLY-5836 in patients with advanced breast cancer and other solid tumors[J]. CANCER RESEARCH, 2024, 84 (09)Varkaris, AndreasIsakoff, StevenPerez, Cesar A.O'Neil, BertHamilton, ErikaConlin, ErinTan, GegeLi, XiaoyanTimm, AlisonSamadani, RaminPuente-Poushnejad, ErikaKwak, EuniceMar, Brenton G.Schram, Alison M.
- [10] A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Baselga, J.De Jonge, M. J.Rodon, J.Burris, H. A., IIIBirle, D. C.De Buck, S. S.Demanse, D.Ru, Q. C.Goldbrunner, M.Bendell, J. C.